CurrentUnitedHealthcarePolicy N/A

Sublingual immunotherapy (SLIT) - Grastek, Oralair, Ragwitek, Odactra

Prior authorization and reauthorization criteria for sublingual immunotherapy products Grastek, Oralair, Ragwitek, and Odactra for treatment of allergic rhinitis; applies to UnitedHealthcare pharmacy benefit management and prescribing providers.

Policy Summary

PayerUnitedHealthcare

PolicySublingual immunotherapy (SLIT) - Grastek, Oralair, Ragwitek, Odactra

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJun 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization with documented diagnosis and confirmatory positive skin or specific IgE testing and timing relative to pollen season.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

4SLIT products covered

12 moAuthorization duration

4–12 wksLead time before season

P&T since 2014Policy review history

Coverage Criteria for SLIT Products

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

ALL of the following

Diagnosis of grass pollen-induced allergic rhinitis.
ANY of the following
- Positive skin test to Timothy grass or cross-reactive grass pollens (e.g., Sweet Vernal, Orchard/Cocksfoot, Perennial Rye, Kentucky Blue/June grass, Meadow Fescue, or Redtop).
- In vitro testing for pollen-specific IgE antibodies for Timothy grass or cross-reactive grass pollens (e.g., Sweet Vernal, Orchard/Cocksfoot, Perennial Rye, Kentucky Blue/June grass, Meadow Fescue, or Redtop).
Treatment is started or will be started at least 12 weeks before the expected onset of the grass pollen season.

Initial Therapy

Covered when ALL of the following are met:

ALL of the following

Diagnosis of grass pollen-induced allergic rhinitis.
ANY of the following
- Positive skin test to any of the five grass species (i.e., Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue grass mixed pollens) or cross-reactive grass pollens (e.g., Cocksfoot, Meadow Fescue, or Redtop).
- In vitro testing for pollen-specific IgE antibodies to any of the five grass species (i.e., Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue grass mixed pollens) or cross-reactive grass pollens (e.g., Cocksfoot, Meadow Fescue, or Redtop).
Treatment is started or will be started at least 4 months before the expected onset of the grass pollen season.

Initial Therapy

Covered when ALL of the following are met:

ALL of the following

Diagnosis of short ragweed pollen-induced allergic rhinitis.
ANY of the following
- Positive skin test to short ragweed pollen.
- In vitro testing for pollen-specific IgE antibodies for short ragweed pollen.
Treatment is started or will be started at least 12 weeks before the expected onset of the short ragweed pollen season.

Initial Therapy

Covered when BOTH of the following are met:

ALL of the following

Diagnosis of house dust mite (HDM)-induced allergic rhinitis.
ANY of the following
- Positive skin test to licensed house dust mite allergen extracts.
- In vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites.

Timing and Coding Considerations

Treatment lead time before pollen season

Grastek (Timothy grass)Treatment must be started at least 12 weeks before the expected onset of the grass pollen season.

Ragwitek (short ragweed)Treatment must be started at least 12 weeks before the expected onset of the short ragweed pollen season.

Oralair (five-grass mix)Treatment must be started at least 4 months before the expected onset of the grass pollen season.

Provider Actions and Authorization Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for these sublingual immunotherapy products. Approval is product-specific and contingent on meeting the initial authorization clinical criteria listed below (diagnosis, confirmatory testing, and timing relative to pollen season).

Products: Grastek, Oralair, Ragwitek, Odactra
Approval requires documentation of diagnosis, confirmatory testing (skin test or specific IgE), and timing (see product-specific start windows)

Step Therapy

Step Therapy Note

Step therapy considerations: ensure the patient is an appropriate candidate for immunotherapy (symptoms not controlled by medications/avoidance or intolerant of medications) before requesting authorization. Document prior medication/avoidance attempts when available to support medical necessity.

Candidate selection: inadequate control with medications and avoidance measures, unacceptable medication adverse effects, or desire to reduce long-term medication use
Include prior treatment history in authorization request to demonstrate stepwise care

Documentation Required

Required Clinical Documentation

Required clinical documentation — include all of the following with the prior authorization request to avoid delays or denial.

Diagnosis: specific diagnosis matching product (Grastek/Oralair — grass pollen-induced allergic rhinitis; Ragwitek — short ragweed pollen-induced allergic rhinitis; Odactra — house dust mite (HDM)-induced allergic rhinitis).
Confirmatory testing: positive relevant skin test OR in vitro specific IgE to the implicated allergen(s) (product-specific lists of grasses or ragweed/HDM as applicable).
Timing: treatment must be started at the product-specific interval before expected pollen season — Grastek and Ragwitek: ≥ 12 weeks before season; Oralair: ≥ 4 months before season; Odactra: per product indication (documented in request).
Treatment intent/start date: documentation that treatment will be or was started within the required timing window.

Denial Risk

Denial Risks and Operational Notes

Denial risks: requests may be denied or auto-processed based on missing documentation, supply limits, or automated claim logic. Confirm documentation and applicable supply/authorization limits prior to submission.

Missing or non-specific diagnosis or lack of confirmatory testing may lead to denial.
Requests outside the specified timing windows (e.g., not started the required weeks/months before season) risk denial.
UnitedHealthcare may approve or deny based solely on prior claims/medication history and diagnosis codes via automated processes.
Supply limits and/or Prior Authorization - Medical Necessity rules may restrict coverage quantities or durations.

Background on Sublingual Immunotherapy

Sublingual immunotherapy (SLIT) products are indicated for patients with allergic rhinitis triggered by specific, identifiable allergens and with documented specific IgE to those allergens. The policy covers four SLIT products with distinct indications: grass pollen products (Grastek and Oralair), short ragweed pollen (Ragwitek), and house dust mite (Odactra). Candidates are typically patients whose symptoms are not adequately controlled with pharmacotherapy and avoidance measures, those who experience unacceptable adverse effects from medications, or patients who wish to reduce long‑term medication use. Product selection and timing of initiation are specific to the allergen and formulation and must be supported by diagnostic confirmation (positive skin test or in vitro testing) as described in the coverage criteria.

Definitions

House dust mite (HDM)-induced allergic rhinitis — definition & confirmatory testing

DefinitionHouse dust mite (HDM)-induced allergic rhinitis: allergic rhinitis caused by Dermatophagoides farinae or Dermatophagoides pteronyssinus.

Confirmatory testing — skin testPositive skin test to licensed house dust mite allergen extracts confirms the diagnosis.

Confirmatory testing — in vitro IgEIn vitro testing demonstrating IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus confirms the diagnosis.

Policy Summary

PayerUnitedHealthcare

PolicySublingual immunotherapy (SLIT) - Grastek, Oralair, Ragwitek, Odactra

Policy CodePolicy N/A

Change TypeNo material change

Effective DateJun 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization with documented diagnosis and confirmatory positive skin or specific IgE testing and timing relative to pollen season.

SourceLink

On This Page